Researchers validate IL13RA2 Biomarker | target for TNBC

JohnSmith

Researchers at Boston University School of Medicine (BUSM), found high expression of the molecule named IL13RA2 (IL13R alpha2) on the surface of the cells in Triple Negative BC.

Similar to the CD47 protein (which is a prognostic factor in almost all cancers), this IL13RA2 protein is also over-expressed in other cancers, including brain, pancreatic, ovarian, and colon.

I've never heard of this protein and did a quick pubmed search. I found ~68 abstracts that mention IL13RA2 going back to the late 90's, but it looks like around ~2006 scientists began to suspect this protein had a role in cancer. This new research validates it as a therapeutic target for triple negative.